SurgeGraph Announces Upcoming AI Image Generation Feature: Content Vision
In a newly uploaded video, SurgeGraph announces their upcoming feature called Content Vision, an advanced…
News
Mitsubishi Motors to Showcase a Fulfilling Mobility Lifestyle that Awakens Drivers’ Adventurous Spirit at the Japan Mobility Show 2023
TOKYO, Sep 25, 2023 – (JCN Newswire) – TOKYO, Sept 25, 2023 – (JCN Newswire)…
Forum Asset Management Launches Initiative in International Institutional Markets And Hires Andrew J. Kavouras to Spearhead Growth
TORONTO, ON / ACN Newswire / September 25, 2023 / Forum Asset Management Inc. collectively…
500 Global Brings Policy, Tech and Venture Capital Together for the Next Decade of Innovation
On October 5th, 2023 the UpNext Summit will bring policymakers, investors, asset allocators and thought…
Cloudflare Helps Companies Reduce Their IT Infrastructure’s Carbon Footprint By Up To 96% by Moving To The Cloud
New report finds that switching enterprise network services from on premises devices to Cloudflare services…
FlexPoint Launches to Revolutionize Payments for Managed Service Providers and the Businesses They Serve
Announces launch of the FlexPoint payments platform supported by GreatAmerica Financial Services® to Offer a…
First Internet Bank Introduces Cash Flow Analysis to Do More Business™ Checking
FISHERS, Ind.–(BUSINESS WIRE)–#SBA–First Internet Bank’s Do More Business™ Checking enables entrepreneurs to accomplish more in…
Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia
Topline data for RECOVER trial on track for October 2023 CUPERTINO, Calif., Sept. 25, 2023…
EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Media Release Subcutaneous EPKINLYTM (epcoritamab) is the first and only bispecific antibody approved in Japan…
MAR Weekly Report_VIRBAC SA_18 to 22 September 2023
Statement of transactions in own shares from September 18, 2023 to September 22, 2023 BNP…
Tenapanor for Hyperphosphatemia Approved in Japan
Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa…
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
REYKJAVIK, Iceland, Sept. 25, 2023 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company…
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar…
BDO ESG Awards: 5th anniversary of ESG Awards kicks off with Carbon Neutrality theme – attracting overwhelming nominations
Hong Kong, Sept 25, 2023 – (ACN Newswire) – BDO, the world’s fifth largest accountancy…
Kawkki Korean Flaming Chicken Ignites IOI Mall Puchong with a Sizzling Korean Culinary Spectacle
PUCHONG, SELANGOR MALAYSIA, Sept 25, 2023 – (ACN Newswire) – The culinary world of Malaysia…
Intact Technology Appoints Randall Fulk as Chief Financial Officer
Former Acumen Solutions Executive Will Lead Intact’s Financial Strategy to Support Continued Growth and Innovation…
Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors
PALO ALTO, Calif.–(BUSINESS WIRE)–Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and…
Carnegie Learning Selects Littera Tutoring Management System to Support High-Dosage Tutoring in Districts Nationwide
WAPPINGERS FALLS, NY–(BUSINESS WIRE)–#education–Beginning this month Carnegie Learning will utilize the Littera Tutoring Management System…
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for…
Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology
Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and…